ERBB2 and breast carcinoma: According to the recent American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines (2021), most HER2-positive (HER2+) breast cancers should be considered for NAC, with exceptions limited to only those with T1a N0 or T1b N0 disease (unless in the clinical trial setting)8.